List of Antibody Drug Conjugates Companies in Netherlands - 7

Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases.

At Avidicure, we invent and develop entirely new antibody therapies, called "AVC-Boosters". Our first-in-class product platform is designed to deliver targeted and potent immune-modulating treatments for patients with cancer or auto-immune diseases.

With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.

Cristal Therapeutics focuses on its unique and proprietary copper free click chemistry CliCr®. CliCr® has a higher stability, enables faster reactions, and generates optimal bioconjugate products. Our mission is to offer our CliCr® technology to partners under license agreements in different diagnostic and therapeutic areas.

Synaffix BV is a biotech company that has established a proprietary, clinical-stage antibody-drug conjugate (ADC) technology platform that delivers best-in-class ADCs (safety and efficacy). Our platform is commercially validated by well over $7.6 billion in technology out-licensing deals with partners including ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio and Kyowa Kirin. These partnerships have rapidly translated Synaffix technology into >20 ADCs currently in development by our partners, where 5 of these have already initiated Phase 1 clinical trials. Through the platform, we can rapidly generate best-in-class ADCs for our partners from any antibody and our patent portfolio protects our proprietary processes and any resulting Products through at least 2039. Additionally, Synaffix technology is being deployed to address unmet medical need in several multi-billion-dollar, high growth market segments such as immune cell engagers and targeted gene therapy. Synaffix BV was acquired by Lonza in May 2023.

Tagworks Pharmaceuticals is a precision oncology company using our proprietary Click-to-Release treatment platform to develop a new standard of care for patients suffering from solid tumors by targeting clinically validated tumor markers that so far have remained out of reach of current therapies. Our lead program, TGW101, is an antibody-drug conjugate (ADC) targeting TAG72, a non-internalizing protein found on the surface of many solid tumor cells. We are developing a pipeline of novel cancer treatments leveraging our Click-to-Release technology in a range of therapeutic modalities, including ADCs and targeted radionuclide therapies. We are headquartered in the Netherlands with operations in the U.S. For more information, visit us at www.tagworkspharma.com.

VHLGenetics is a leading service provider with three business units: in The Netherlands Dr. van Haeringen Laboratorium B.V. (VHL), in Germany Certagen GmbH and in Belgium Dr. van Haeringen Polygen bvba (VHP). For more than 25 years, DNA has been the core of the organization, serving customers with routine DNA tests in non-human species. Utilizing the latest DNA technologies has enabled the VHLGenetics to grow quickly since 1993. Nowadays, our experienced laboratories offer more than 500 routine DNA tests for animals, plants and microorganisms. A few examples of routine tests in the portfolio of VHLGenetics include parentage verification, genotyping genetic traits like causal mutations, coat variation and the detection of pathogens (ParaTBC or QFever). For more information, please visit our website at www.vhlgenetics.com.